The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
Long-lasting antiretroviral drugs injected monthly present a ‘remarkable milestone’ in treatment options for people living with HIV
Without urgent action, HIV drug resistance is set to derail the HIV response and presents a significant threat to public health, the World Health Organization (WHO) warns today.
‘Surprising’ research from Conference on Retroviruses and Opportunistic Infections (CROI) shows drug resistance does not impact test-and-treat roll-out in South Africa – at least in the short term.
HIV is more proactively monitored among urban HIV patients than rural patients, and drug resistance and treatment failure is less prevalent. However outcomes for second line treatment remain similar.
Treatment scale-up has had major public health benefits. But where resources are scarce, interventions to keep people in care could be more cost-effective than moving to treat everybody living with HIV after diagnosis.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.
Concerns have been raised about the shortage of antiretroviral drugs available for people living with HIV in Venezuela, which is in the midst of a mounting health crisis.
Resistance to the commonly prescribed antiretroviral drug tenofovir is ‘surprisingly common’, according to findings published in the Lancet Infectious Diseases last week.